Navigation Links
Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System

DURHAM, N.C., Nov. 1 /PRNewswire/ -- Regado Biosciences today announced the enrollment of the first patient in a multi-center, open-label, randomized Phase IIa clinical study, named REVERSAL-PCI, of its REG1 Anticoagulation System. The patient was enrolled at Black Hills Cardiology in Rapid City, SD. The study will enroll 26 patients undergoing elective Percutaneous Coronary Intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon angioplasty dilatation and stenting on patients at low-risk for complications associated with therapy-related bleeding or heart attack. The REG1 Anticoagulation System is a combination of RB006, an intravenous anticoagulant, and its highly specific, rapidly acting antidote, RB007.

All patients will be pretreated with clopidogrel and aspirin to inhibit platelet activity. Primary procedural success will be defined by absence of significant bleeding events up to hospital discharge or 48 hours post stenting, and by absence of death, nonfatal heart attack, or need to repeat revascularization up to day 14. The study will be conducted at sites in the United States and Argentina.

"There is a significant and immediate need for an anticoagulant therapy that can be adjusted quickly and easily based on the changing medical condition of the patient. Our Phase I studies in healthy volunteers and in patients with stable coronary artery disease showed REG1 provided a safe, potent, and quickly reversible anticoagulant effect," stated Douglas Gooding, Chief Executive Officer of Regado Biosciences. "Our plan is to build on our existing data set and initiate several additional Phase II studies to establish proof of concept in a wide range of coronary revascularization procedures."

Regado has conducted three Phase I clinical studies of REG1, all of which demonstrated the anticoagulation system is safe and the antidote effective in both healthy volunteers and in older patients with stable coronary artery disease.

"I am very pleased with the results of this first clinical experience with the REG1 system during a stent procedure. We anticipate this drug will fulfill multiple unmet needs in the care of heart patients," stated Mauricio Cohen, MD, the Director of Cardiology Clinical Trials at the University of North Carolina and Principal Investigator of the REVERSAL-PCI study. "The lack of a safe and at the same time efficacious reversible blood thinner has been a major problem for cardiologists performing invasive catheterization procedures. We are hopeful that this agent will revolutionize the approach to anticoagulation during catheter-based interventions and the care of heart attack patients."

Currently, heparin and protamine are the only approved therapeutic/antidote drug pair used in surgical procedures, such as PCI. However, these drugs have well-known limitations, including the risk for developing heparin-induced thrombocytopenia (with or without thrombosis), as well as protamine-associated side effects, such as anaphylaxis and systemic hypotension.

About REG1 Anticoagulation System

Regado's lead product candidate, REG1, is the first specific, direct-acting, antidote-controlled anticoagulant ever described. Regado is developing REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures. These procedures, which include coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), put patients at a high-risk for therapy-related bleeding complications. REG1 is being developed initially to increase therapeutic flexibility and improve patient outcomes in coronary revascularization procedures.

REG1 is a two-component system, consisting of an aptamer-based anticoagulant and its matched antidote. The REG1 anticoagulant component (RB006) is a single-stranded, nucleic acid aptamer. RB006 selectively and potently binds to and inhibits Factor IXa, a protein that is critical to blood coagulation. The antidote component, RB007, is a complementary nucleic acid that binds to and neutralizes RB006. The binding of RB007 to RB006 causes the predictable and rapid reversal of RB006 that allows the patient's blood to return to normal.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the discovery and development of drug:antidote systems. Regado's drug:antidote systems are designed to give physicians the ability to fine-tune the therapeutic effect desired for each patient and in each setting. A spin-out of the Department of Surgery at Duke University Medical Center, Regado was created to answer the therapeutic needs identified by its scientific founders.

The Company's proprietary platform technology enables the discovery of oligonucleotide-based drug-antidote pairs to any target protein. Regado initially is focusing its discovery and development efforts on the acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles. Potential future indications for Regado's technology include acute coronary syndromes and other coronary revascularization procedures that would benefit from the availability of an antidote-reversible agent.

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Marker Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
Breaking Medicine Technology:
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women on ... organizations in the country. They have overseen financial turnarounds, shown commitment to their ... healthcare industry as a whole through their advocacy and professional efforts. , Becker's ...
(Date:11/26/2015)... ... ... Inevitably when people think Thanksgiving, they also think Holiday sales and start ... and Cyber Monday massage chair sales to receive the best pricing on ... find the best massage chair deals, they can see all of the coupons in ...
(Date:11/26/2015)... ... ... PRMA Plastic Surgery is updating their record books yet again with an ... breast reconstruction surgery! , “What an accomplishment for the PRMA team, says Dr. ... an honor to have served all of these women.” , PRMA is one of ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers ... on mammography, according to a study published online in the journal Radiology. Researchers ... mammography may necessitate a change in treatment. , Breast MRI is the most ...
Breaking Medicine News(10 mins):